SNPMiner Trials: Clinical Trial Report
Report for Clinical Trial NCT01134120
Developed by Shray Alag, 2019.
SNP Clinical Trial Gene
The purpose of this study is to find out the safe dose range of the study drug in patients
with myeloproliferative disorders.
Name: LY2784544
Description: LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.Type: Drug
LY2784544
Primary Outcomes
Measure: Determination of a recommended Phase 2 dosing regimen
Time: Time of first dose until last dose
Measure: Number of participants with clinical significant effects
Time: Time of first dose until last dose
Secondary Outcomes
Measure: Preliminary pharmacokinetics of LY2784544 (Cmax)
Time: Part A1: Day 1,2,15, and 29; Part A2: Day 7, 14, 21, 28, 29, 56, and 57; Part B: Day 1, 29, 57, and 113
Measure: Preliminary pharmacokinetics of LY2784544 (AUC)
Time: Part A1: Day 1,2,15, and 29; Part A2: Day 7, 14, 21, 28, 29, 56, and 57; Part B: Day 1, 29, 57, and 113
Measure: Malignant clone burden
Time: Part A1: Baseline (2 times), Weeks 13, 21 and every 6 months while patient is on study; Parts A2 and B: Baseline (2 times), Weeks 5, 8, 17, 25 and every 6 months while patient is on study
Purpose: Treatment
Single Group Assignment
There is one SNP
SNPs
1 V617F
A Phase 1 Study of LY2784544 in Patients With JAK2 V617F-Positive Myeloproliferative Disorders. --- V617F ---
has post-ET MF
- Have a quantifiable JAK2 V617F mutation
- Have discontinued all previous approved therapies for myeloproliferative disorders,
including any chemotherapy, immunomodulating therapy (for example, thalidomide,
interferon-alpha), immunosuppressive therapy (for example, corticosteroids greater
than 10 mg/day prednisone or equivalent), radiotherapy, and erythropoietin,
thrombopoietin, or granulocyte colony stimulating factor for at least 14 days and
recovered from the acute effects of therapy. --- V617F ---
HPO Nodes
HPO:Myeloproliferative disorder
Genes 12
GATA2 MPL SH2B3 PDGFRA BCR JAK2 PDGFRB ABL1 THPO CALR RUNX1 GATA1 hr>Polycythemia
Genes 15
PKLR SH2B3 VHL JAK2 ENG EPO EPOR SLC30A10 EPAS1 EGLN1 BPGM ACVRL1 CYB5R3 FH GATA1 hr>Thrombocytosis
Genes 25
MPL IFNGR1 CD55 JAK2 TET2 ELANE RPS19 RPSA HMGCL TMEM173 ABL1 THPO RUNX1 ZMPSTE24 LMNA SH2B3 HBB BCR ACAT1 ADA2 MTHFD1 CALR TTC37 TBC1D24 PMM2 hr>